Payment overview · 2025
General Payments
$619.92
32 reported records · 11 companies
Healthcare provider profile · identity verified
Daryl Carson Wiley, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · THOMSON, GA · NPI 1508859448
Verified facts
What the public records show
CMS Open Payments records show Daryl Carson Wiley, M.D. received $619.92 in general payments during 2025 across 32 reported records.
GlaxoSmithKline, LLC. accounted for 27.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Vraylar by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $167.39 | 27.0% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $142.32 | 23.0% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $91.88 | 14.8% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $64.97 | 10.5% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $45.12 | 7.3% | 2 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $32.67 | 5.3% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $24.00 | 3.9% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $16.36 | 2.6% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $15.09 | 2.4% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $13.56 | 2.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $6.56 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $619.92 | 32 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $156.65 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $142.32 | 10 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $83.92 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $76.29 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $64.97 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $50.92 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $45.12 | 2 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $32.67 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $31.65 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $24.00 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $16.36 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $16.36 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.59 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $15.09 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $13.56 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $10.74 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $6.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 131 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 44 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
44 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
99 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
131 | 28 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1210 | 164 |
| Amlodipine Besylate | Amlodipine Besylate | 1147 | 172 |
| Levothyroxine Sodium | Levothyroxine Sodium | 745 | 117 |
| Losartan Potassium | Losartan Potassium | 673 | 108 |
| Lisinopril | Lisinopril | 658 | 135 |
| Trazodone Hcl | Trazodone Hcl | 656 | 63 |
| Potassium Chloride | Potassium Chloride | 612 | 67 |
| Eliquis | Apixaban | 579 | 54 |
| Mirtazapine | Mirtazapine | 565 | 50 |
| Famotidine | Famotidine | 558 | 78 |
| Gabapentin | Gabapentin | 543 | 97 |
| Metformin Hcl | Metformin Hcl | 476 | 129 |
| Tamsulosin Hcl | Tamsulosin Hcl | 473 | 75 |
| Pantoprazole Sodium | Pantoprazole Sodium | 458 | 74 |
| Donepezil Hcl | Donepezil Hcl | 451 | 31 |
| Omeprazole | Omeprazole | 446 | 98 |
| Quetiapine Fumarate | Quetiapine Fumarate | 434 | 26 |
| Carvedilol | Carvedilol | 397 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 396 | 45 |
| Hydralazine Hcl | Hydralazine Hcl | 369 | 36 |
| Furosemide | Furosemide | 354 | 71 |
| Levetiracetam | Levetiracetam | 344 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 339 | 60 |
| Sertraline Hcl | Sertraline Hcl | 338 | 62 |
| Simvastatin | Simvastatin | 309 | 48 |
| Allopurinol | Allopurinol | 277 | 41 |
| Montelukast Sodium | Montelukast Sodium | 256 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 249 | 59 |
| Hydrochlorothiazide | Hydrochlorothiazide | 238 | 65 |
| Alprazolam | Alprazolam | 237 | 46 |
| Pravastatin Sodium | Pravastatin Sodium | 236 | 63 |
| Escitalopram Oxalate | Escitalopram Oxalate | 232 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 223 | 83 |
| Memantine Hcl | Memantine Hcl | 204 | 11 |
| Tramadol Hcl | Tramadol Hcl | 203 | 77 |
| Buspirone Hcl | Buspirone Hcl | 195 | 27 |
| Meloxicam | Meloxicam | 195 | 40 |
| Citalopram Hbr | Citalopram Hydrobromide | 188 | 19 |
| Metoprolol Succinate | Metoprolol Succinate | 174 | 44 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 173 | 40 |
| Clonazepam | Clonazepam | 164 | 34 |
| Atenolol | Atenolol | 139 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 135 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 134 | 52 |
| Olanzapine | Olanzapine | 134 | suppressed |
| Ozempic | Semaglutide | 131 | 28 |
| Alendronate Sodium | Alendronate Sodium | 120 | 18 |
| Lovastatin | Lovastatin | 115 | 18 |
| Methocarbamol | Methocarbamol | 112 | 33 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 110 | 33 |
| Finasteride | Finasteride | 102 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 102 | 33 |
| Myrbetriq | Mirabegron | 100 | 12 |
| Jardiance | Empagliflozin | 99 | 21 |
| Divalproex Sodium | Divalproex Sodium | 98 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 97 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 97 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 96 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 96 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 93 | 23 |
| Bupropion Xl | Bupropion Hcl | 89 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 89 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 88 | 22 |
| Xarelto | Rivaroxaban | 87 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 86 | 16 |
| Valsartan | Valsartan | 86 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 85 | suppressed |
| Spironolactone | Spironolactone | 85 | 16 |
| Sucralfate | Sucralfate | 81 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 79 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 78 | 23 |
| Fenofibrate | Fenofibrate Nanocrystallized | 76 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 70 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 67 | 27 |
| Doxazosin Mesylate | Doxazosin Mesylate | 64 | 20 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 63 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 63 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 63 | 28 |
| Lorazepam | Lorazepam | 61 | 25 |
| Meclizine Hcl | Meclizine Hcl | 61 | 24 |
| Novolog Flexpen | Insulin Aspart | 61 | 16 |
| Amiodarone Hcl | Amiodarone Hcl | 58 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 57 | suppressed |
| Dutasteride | Dutasteride | 57 | 12 |
| Rivastigmine | Rivastigmine Tartrate | 56 | suppressed |
| Nifedipine Er | Nifedipine | 55 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 55 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 53 | suppressed |
| Azithromycin | Azithromycin | 53 | 49 |
| Breo Ellipta | Fluticasone/Vilanterol | 53 | 12 |
| Estradiol | Estradiol | 53 | 13 |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 53 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 53 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 52 | 19 |
| Prednisone | Prednisone | 52 | 27 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 52 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 52 | suppressed |
| Torsemide | Torsemide | 52 | suppressed |
| Januvia | Sitagliptin Phosphate | 50 | 13 |
| Mesalamine | Mesalamine | 50 | suppressed |
| Baclofen | Baclofen | 49 | suppressed |
| Metolazone | Metolazone | 48 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 47 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 47 | 17 |
| Risperidone | Risperidone | 46 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 45 | 23 |
| Colchicine | Colchicine | 44 | 13 |
| Ibuprofen | Ibuprofen | 44 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 44 | 13 |
| Fenofibrate | Fenofibrate | 43 | 14 |
| Enulose | Lactulose | 42 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | 12 |
| Diltiazem 24hr Er | Diltiazem Hcl | 41 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 41 | 22 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 40 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 40 | 23 |
| Pregabalin | Pregabalin | 39 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 39 | 11 |
| Aripiprazole | Aripiprazole | 36 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 36 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 35 | suppressed |
| Cephalexin | Cephalexin | 34 | 17 |
| Clonidine Hcl | Clonidine Hcl | 34 | suppressed |
| Diazepam | Diazepam | 33 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 33 | suppressed |
| Trulicity | Dulaglutide | 33 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 32 | suppressed |
| Entresto | Sacubitril/Valsartan | 31 | suppressed |
| Rexulti | Brexpiprazole | 31 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 31 | suppressed |
| Vraylar | Cariprazine Hcl | 31 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 30 | 13 |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 29 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 29 | 23 |
| Tenivac | Tetanus-Diphtheria Toxoids/Pf | 29 | 29 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Bumetanide | Bumetanide | 28 | suppressed |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Klor-Con M20 | Potassium Chloride | 28 | suppressed |
| Repatha Sureclick | Evolocumab | 28 | suppressed |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 27 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 27 | suppressed |
| Primidone | Primidone | 27 | suppressed |
| Topiramate | Topiramate | 27 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Nystatin | Nystatin | 26 | 16 |
| Rybelsus | Semaglutide | 26 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Fluconazole | Fluconazole | 25 | 16 |
| Linzess | Linaclotide | 25 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Mitigare | Colchicine | 24 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 24 | 11 |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 22 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Praluent Pen | Alirocumab | 22 | suppressed |
| Calcitriol | Calcitriol | 21 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 21 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 21 | suppressed |
| Lamotrigine | Lamotrigine | 21 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 21 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | 12 |
| Ondansetron Odt | Ondansetron | 19 | 14 |
| Promethazine Hcl | Promethazine Hcl | 19 | suppressed |
| Auryxia | Ferric Citrate | 18 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 15 |
| Glipizide Er | Glipizide | 18 | suppressed |
| Telmisartan | Telmisartan | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Carbamazepine | Carbamazepine | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 17 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 14 |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | suppressed |
| Timolol Maleate | Timolol Maleate | 16 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 15 | suppressed |
| Methimazole | Methimazole | 15 | suppressed |
| Anastrozole | Anastrozole | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Cefdinir | Cefdinir | 14 | 13 |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 14 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 14 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 13 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 12 | suppressed |
| Aliskiren | Aliskiren Hemifumarate | 11 | suppressed |
| Amantadine | Amantadine Hcl | 11 | suppressed |
| Captopril | Captopril | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 11 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $619.92 · 32 records | GlaxoSmithKline, LLC. | AREXVY, Briviact, CAPLYTA, CAPVAXIVE, GARDASIL 9, Kerendia, MOUNJARO, Ozempic, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, ZEPBOUND, ZORYVE | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error